BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230530
DTEND;VALUE=DATE:20230602
DTSTAMP:20260516T062328
CREATED:20230222T124243Z
LAST-MODIFIED:20230222T124243Z
UID:36641-1685404800-1685663999@www.pharmajournalist.com
SUMMARY:5th Treg Summit
DESCRIPTION:With investment into the Treg field at an all time high\, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity\, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic\, it remains vital for Treg trailblazers to come together to recognize therapy efficacy\, determine safety and translate the next-generation of therapies into the clinic. \nThe Treg Summit returns for the 5th year to unite this dedicated community of industry and academic experts\, and remains the go-to industry forum to advance both cell and non-cell based approaches to unlock the potential of Tregs to treat indications with huge unmet clinical need. \nWith 3 jam-packed days of content across CAR-\, TCR– and polyclonal Tregs as well as IL-2\, muteins and small molecules\, you won’t want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances\, discuss challenges and discover next-gen methods to take Treg therapies to the next level. \nWhy Attend Now? \n\nOver $2 billion has been thrown into the Treg space in the past 8 months alone\, reflecting the potential of these therapies\n2022 saw the first-ever dosing of a human with a CAR-Treg cell therapy paving the way for the rest of the engineered Treg field\nVital clinical updates determine the safety and efficacy of Treg modulating therapies\n\nSecure your place today – https://ter.li/jddnbx
URL:https://www.pharmajournalist.com/event/5th-treg-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260516T062328
CREATED:20230208T093703Z
LAST-MODIFIED:20230208T093703Z
UID:36555-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy Potency Assay Summit
DESCRIPTION:The 2nd Cell Therapy Potency Assay will gather 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements. \nWhether you are submitting your first IND or gearing up towards BLA submission\, this critical meeting of minds is your premier opportunity to join the likes of bluebird bio\, Arsenal Bio\, Takeda\, Merck\, Sana Biotechnology and more\, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development. \nLeave this meeting equipped with industry insights to understand what potency assays are showing\, develop practical\, compatible\, reproducible assays; and better characterize your cell therapy products for targeted\, untargeted\, allogeneic and autologous platforms in oncology and non-oncology indications. \nTo know more visit: https://ter.li/zc871s
URL:https://www.pharmajournalist.com/event/2nd-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260516T062328
CREATED:20230307T092630Z
LAST-MODIFIED:20230307T092630Z
UID:36769-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:5th Age-Related Disease Therapeutics Summit
DESCRIPTION:Whether it’s in cardiovascular disease\, Alzheimer’s or osteoarthritis\, therapeutic innovations to target the mechanisms of aging are making significant headway to clinical trials. With increased investments and recognition\, along with the escalation of the burden of age-related disease\, research and development to meet this unmet medical need has never been more important. \nThe 5th Age-Related Disease Therapeutics Summit is the only industry-focused meeting dedicated to uniting 100+ biopharma drug developers\, pioneering academics\, and prominent investors striving to develop effective\, novel drugs that promote healthy aging and overcome major translational and regulatory obstacles. \nJam-packed with the most cutting-edge insights and opportunities to reunite with and hear from your peers on the next steps forward in developing the safest and most efficacious drug to promote a healthier and enhanced quality of life. \nTo know more visit: https://ter.li/sl5og6
URL:https://www.pharmajournalist.com/event/5th-age-related-disease-therapeutics-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260516T062328
CREATED:20230202T110957Z
LAST-MODIFIED:20230202T110957Z
UID:36469-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotides for CNS Summit
DESCRIPTION:With approvals in siRNA technology\, more ASOs hurtling towards human trials in neurology\, and exciting headlines in Alzheimer’s and ALS\, the draw of CNS targets for oligonucleotides has never been greater. Massive investments and growing pipelines in pharma and biotech alike are working to make these life-changing therapies a reality for previously undruggable targets. \nJoin 100+ experts and dedicated scientists at the 3rd Oligonucleotides for CNS\, the definitive industry forum bringing together leaders to problem-solve\, explore invention\, and inspire the creation of next-generation oligonucleotide drugs for neurological disorders. Gather with specialists from Biogen\, Ionis\, Genentech\, Eli Lilly\, Servier\, and Stoke\, spanning disciplines of biology\, chemistry\, toxicology\, and clinical innovation. \nTackle genomic target validation\, backbone chemistry\, effective intracellular delivery\, and potency\, increased stability for reduced dosing\, novel cerebral organoids\, CNS device delivery\, and CSF oligo distribution to uncover the best approaches for each phase in your pipeline. Take away invaluable lessons that will translate directly into optimizing your oligonucleotide pipeline for the CNS. \nTo know more visit: https://ter.li/i5y7zn
URL:https://www.pharmajournalist.com/event/3rd-oligonucleotides-for-cns-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260516T062328
CREATED:20230207T095425Z
LAST-MODIFIED:20230207T095425Z
UID:36545-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders Summit Europe
DESCRIPTION:Returning as the pinnacle event in the industry\, the 4th Annual Gene Therapy for Neurological Disorders Summit Europe (6-8 June 2023\, Amsterdam) enables you to bring your gene therapy to patients in Europe. This year’s content takes a greater focus on: \n\nInnovation in preclinical models and vector technology\nShowcasing novel approaches to improve delivery in a safe manner\nOptimizing administration route to reduce the patient\nUnderstanding what needs to be done to crack the European market\n\nDownload the agenda to find out more – https://ter.li/1mmd4t \nCovering both neurodevelopmental and neurodegenerative disorders\, join 80+ of your peers in Amsterdam this June. We’ll be welcoming those leading biopharma and academia\, working in preclinical\, clinical and market access to help get safer\, more efficacious gene therapies for neurological disorders to market in Europe. \nAs the gene therapy community gets a second wind and as the clinical promise in neurology begins to be realised\, now is the time to get your hands on the latest innovations in this field to bring safe\, efficacious and commercially successful products to market in Europe.  \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/azxig5
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders-summit-europe/
LOCATION:Room Mate Aitana\, IJdok 6\, 1013 MM\, Amsterdam\, 1013 MM\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230612
DTEND;VALUE=DATE:20230614
DTSTAMP:20260516T062328
CREATED:20230323T114637Z
LAST-MODIFIED:20230323T114637Z
UID:36890-1686528000-1686700799@www.pharmajournalist.com
SUMMARY:6th Annual Pre-Filled Syringes West Coast Conference
DESCRIPTION:Assessing Device Development and Regulation for Advanced Innovation\nSponsors: Datwyler\, Haselmeier\, Mitsubishi Gas Chemical\, Nemera\, ZEON \nExhibitors: Credence MedSystems\, Kymanox\, Noble\, Owen Mumford Pharmaceutical Services\, SCHERDEL Medtec \nSAE Media Group’s 7th Annual Pre-Filled Syringes West Coast Conference will be back for 2023 in San Diego to bring together the device developers\, innovative biotech\, and big pharma. \nThis year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \nWith the injectable drug delivery industry rapidly advancing year-to-year\, administration using pre-filled syringes\, auto-injectors\, and pen-injectors are increasingly common. Innovations in device technology\, such as connected devices are leading the way in device design in addition to injectable delivery devices for novel and large volume drugs. With the need for self-administration growing\, there is an enhanced demand for on-body injectors and digitalised health as well as patient centricity. We are beginning to see environmental sustainability being incorporated into aspects of device lifecycle from design to manufacturing and the use of the device. This year’s conference looks to address these hot topics through case studies and industry insights. \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring delegates key insights to enhance their drug device portfolio\, but it will also give them the opportunity to network with key industry players.  \nBenefits of Attending: \n\nEngage with industry representatives about the latest technologies and advances within the injectable device market and directions to take to advance your device portfolio\nGain insight into new technologies for wearable injectors he delivery of novel and large volume drugs\nUnderstand the latest regulatory requirements and guidance to ensure your combination products are compliant such as meeting essential performance requirements\nDelve into aspects of primary packaging such as material components to consider during device design to ensure drug stability and safety\nExplore how digital technologies such as companion apps are being incorporated into drug delivery devices to improve user-centricity\n\nWho should attend: \nDirectors\, Heads of Departments and Managers for the following areas: \n\nDevice Development\nDevice Engineering\nCombination Product Development\nDrug Delivery Devices\nPrimary Packaging Development\nDigital Health\nLarge Volume Drug Delivery\nNovel Drug Product Formulation\nRegulatory Affairs\n\nEarly Bird Rates: \n\nEB1 – 28 Feb 2023 – US$400\nEB2 -31 March 2023 – US$200\nEB3 – 28 April 2023 – US$100\n\nAdditional Contact Info: \nT: +44 (0)20 7827 \nE: Hannah.Blake@saemediagroup.com \nW: http://www.prefilled-syringes-westcoast.com/PharmaJournalist-El
URL:https://www.pharmajournalist.com/event/6th-annual-pre-filled-syringes-west-coast-conference/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260516T062328
CREATED:20230228T084503Z
LAST-MODIFIED:20230228T084623Z
UID:36697-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Patient Engagement
DESCRIPTION:As the global healthcare system accelerates its acceptance of gene therapies as one-time\, potentially curative\, treatment options for rare diseases\, the role of patient engagement in informing drug development strategy is evolving. \nAt this interface lies the 3rd Gene Therapy Patient Engagement Summit\, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers\, along with patient groups and patients themselves. Talks\, workshops\, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process. \nJoin us in Boston this summer to gain the actionable insights\, tools\, and strategies you need to better implement patient input into patient-centric gene therapy programs. \nTo know more visit: https://ter.li/rbofji
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-patient-engagement/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260516T062328
CREATED:20230320T154738Z
LAST-MODIFIED:20230320T154738Z
UID:36873-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:Temperature Control and Logistics Summit
DESCRIPTION:Advance your end-to-end logistics strategy to deliver vital therapeutics at the RIGHT TIME\, RIGHT PLACE and the RIGHT TEMPERATURE \nJoin us in Frankfurt in June 2023 in a brand-new venue at the heart of Europe\, as once again\, we return live and in-person for 3 days of interactive sessions\, collaborative roundtables as well as formal and informal networking to maximise the value of shared insights and open discussions. \nWe meet at a time of great challenge and opportunity. How can we mitigate risk and ensure quality whilst adopting the new technologies essential to future success? In what ways can we bolster the resilience of our supply chains without compromising operational agility? How can we build a supply chain and logistics network that is both effective and environmentally sustainability? \nOnly in partnering across the supply chain can we confront these challenges; and as a community that thrives on innovation and collaboration\, we’ve built a programme centred on the fundamental challenges of our time\, including how we: \n>> Drive Digital Transformation Throughout The Supply Chain To Achieve Full End-To-End Visibility\n>>Enhance Supply Chain & Logistics Network Design To Bolster Resilience\, Security & Efficiency\n>> Partner Across The Network To Meet The Demands of An Increasingly Complex Operating Environment\n>> Leverage New Packaging Innovation To Ensure Quality & Demonstrate Regulatory Compliance\n>> Build An Environmentally Sustainability Temperature Controlled Supply Chain \nTCL 2023 will provide a deep-dive into what these industry developments mean for Pharmaceutical Logistics\, Quality Assurance & Supply Chain practitioners and focus on delivering a mix of interactive sessions\, which will enable delegates to leverage the collective knowledge of their peers and brainstorm solutions to the challenges\, which the industry is facing. \nTCL doesn’t just stand for Temperature Control and Logistics\, now it also stands for Transformation\, Collaboration and Learning! >> Download the full agenda to view full speaker line-up\, discussion details\, sponsorship opportunities\, and more!
URL:https://www.pharmajournalist.com/event/temperature-control-and-logistics-summit/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="IQPC Limited":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260516T062328
CREATED:20230503T050638Z
LAST-MODIFIED:20230503T050638Z
UID:37123-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd ILD Summit
DESCRIPTION:Returning for the 3rd year\, the ILD Summit will lean into the industry’s key challenges\, explore pipeline opportunity development\, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs. \nTo know more visit: https://ter.li/wc2uto
URL:https://www.pharmajournalist.com/event/3rd-ild-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T062328
CREATED:20230314T122048Z
LAST-MODIFIED:20230314T122048Z
UID:36825-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:Next Gen Inhalation Delivery Summit
DESCRIPTION:With exciting developments in pioneering inhaled drug products from Moderna\, Vertex\, ReCode Therapeutics\, and Pieris Pharmaceuticals\, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029\, achieving cell-specific delivery\, and optimized stability remain vital challenges. \nThis June\, the hotly anticipated Next Gen Inhalation Delivery Summit will debut\, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD\, asthma\, IPF\, lung cancer or infectious disease\, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery. \nBe part of the conversation in Boston this June\, where we unpick: \n\nOvercoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit\nAdvancing your inhalation formulation techniques for improved stability and longer shelf-lives\nEnsuring device-formulation compatibility with patient compliance and patient convenience\n\nWith key speakers from the likes of Janssen\, Avalyn Pharma\, and FDA\, exciting content\, and networking opportunities\, you cannot afford to miss out! \nTo know more visit: https://ter.li/hlg9tw
URL:https://www.pharmajournalist.com/event/next-gen-inhalation-delivery-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T062328
CREATED:20230330T101610Z
LAST-MODIFIED:20230330T102722Z
UID:36955-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Exciting results are expected this year\, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73\, CD39 and A2AR! \nTo ensure the community can capitalize on this\, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston\, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73\, CD39\, A2A and A2B focused therapeutics. \nJoin this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage\, utilize novel technologies and approaches through translation to clinical development to improve patient selection\, and discover new ways of finding mono and combo therapy approaches to increase potency and safety. \nTop Speakers includes: \n\nAlex Gaither\, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates\nChangyun Hu\, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more\nJoanne Lager\, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure\n\n& 15+ more expert speakers! \nDownload your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5 \nInterested in speaking? Contact info@hansonwade.com \nInterested in sponsoring? Contact sponsor@hansonwade.com
URL:https://www.pharmajournalist.com/event/2nd-annual-adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230621
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T062328
CREATED:20230309T105108Z
LAST-MODIFIED:20230309T105108Z
UID:36775-1687305600-1687478399@www.pharmajournalist.com
SUMMARY:Antimicrobial Resistance Connect Europe
DESCRIPTION:This event will take place in London on 21-22 June 2023 in London\, focusing on the three biggest priorities enabling growth in the AMR field – Innovation\, Investment & Policy – AMR Connect enables you to foster connections with key stakeholders in anti-microbial research and build actionable next steps to combat the silent pandemic. \n \nAMR Connect provides your team with the opportunity to create actionable steps within an interdisciplinary environment\, creating a unified approach across sectors. The demand to innovate and advance the way we tackle resistance is paramount and commanding the attention of nations globally – book your place now and join us in tackling the silent pandemic. \nBenefits of attending \n\nWith AMR considered one of the top 10 public health threats globally\, uncover how different regions are developing effective policy guidelines and incentive schemes that work for their region – with sessions from ReAct Latin America\, Asia-Europe Foundation\, WHO and many more.\nApply for the Innovation Showcase\, showcasing your state-of-the-art research in drug development\, diagnostics or one health in front of our room of investors\, pharma and solution providers.\nStreamline your route from discovery to market through case studies from Arrepath and Madam Therapeutics on the utilisation of AI/ML to reduce drug development timescales.\nMeet your next partner and foster connections across stakeholders through future-focussed roundtables on the biggest challenges impacting the field – including regulation\, policy and the future of anti-infectives.\n\nTake advantage of the early bird discount ending on 24 March. Book now to SAVE up to £700.
URL:https://www.pharmajournalist.com/event/antimicrobial-resistance-connect-europe/
LOCATION:LONDON\,UK
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230627
DTEND;VALUE=DATE:20230630
DTSTAMP:20260516T062328
CREATED:20230207T095639Z
LAST-MODIFIED:20230207T095639Z
UID:36549-1687824000-1688083199@www.pharmajournalist.com
SUMMARY:3rd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:As the biggest industry-led meeting on novel vector development\, the 3rd Annual Next Generation Gene Therapy Vectors Summit (June 27-29\, 2023 | Boston\, MA) will bring together 100+ key opinion leaders to help solve the safety\, efficiency\, and scalability challenges of the next generation of vectors. \nIndustry heavyweights such as Novartis\, Spark Therapeutics\, Capsida Biotherapeutics\, and Dyno Therapeutics will deliver data-led seminars\, workshops\, and panels to aid in the progression of promising vector designs from discovery to clinical trials. \nDownload the brochure to see the full agenda – https://ter.li/b6qdwn \nUniting industry pioneers such as Dave Chu (Capsida Biotherapeutics)\, Sean Armour (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jing Liao (Alexion Pharmaceuticals)\, and others – this summit will be your ultimate roadmap to the future of the industry as it upgrades to the next generation of vectors. \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/qlplw9
URL:https://www.pharmajournalist.com/event/3rd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230628
DTEND;VALUE=DATE:20230701
DTSTAMP:20260516T062328
CREATED:20230413T095125Z
LAST-MODIFIED:20230413T095125Z
UID:37050-1687910400-1688169599@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement Drug Development Summit
DESCRIPTION:The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America’s definitive microbiome drug development event – and it’s back bigger and better than ever! \nThe microbiome-based therapeutic market is rapidly evolving\, and it’s more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches. \nJoin us\, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways\, host-microbe relationships in novel preclinical models\, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies\, new smart clinical trial data\, and GMP compliant manufacturing for stable products. \nWith more speakers\, content\, and networking than ever before\, this is set to be the best version of the event yet and you cannot afford to miss it! \nTo know more visit: https://microbiome-summit.com/
URL:https://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR